Gatifloxacin (Zymaxid)

Trade Name : ZYMAXID

Allergan, Inc.

SOLUTION/ DROPS

Strength 5 mg/mL

GATIFLOXACIN Quinolone Antimicrobial [EPC],Quinolones [CS]

Delivery Process

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

We’ll Get in Touch

Once we review your request, we’ll send you an estimated price for the medicine within 2-5 days.

Confirmation and Payment

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Submit a Request

You can fill in a request for your medicine through the form provided. You can access the form by clicking on the ‘Get Price’ button.

Product information is meant for

Wholesalers Suppliers Exporters Doctors MOH Tender Supplies Hospitals Brand CROs Comparator Supplies Generic Cooperate Sourcing Individual Patients Indian Institutional Buyers

Disclaimer

Trade Marks displayed in compliance with provisions of: Trademark Act, 1999 u/s 30 and 30 (1) of "Fair use"

GNH India is WHO GDP and ISO 9001 2015 Certified Pharmaceutical Wholesaler/ Supplier/ Exporters/ Importer from India of Gatifloxacin (Zymaxid) which is also known as ZYMAXID and Manufactured by Allergan, Inc.. It is available in strength of 5 mg/mL per ml. Read more

Gatifloxacin (Zymaxid) is supplied for Tenders/ Emergency imports/ Un - licensed, Specials, Orphan drug/ Name patient line/ RLD supplies/ Reference listed drugs/ Comparator Drug/ Bio-Similar/ Innovator samples For Clinical trials.  Click to know price.     Read less

Packaging and Delivery

Validated Cold Chain Shipment

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Inquire directly from our website and get 5% off on any medicine!

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Read more

About GNH

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

We deliver your medicines through a validated cold chain shipment process. This process is used as these medicines need to manufactured, transported and stored at very specific temperatures, utilizing thermal and refrigerated packaging methods.

Read more
  • No data
  • No data
  • ZYMAXID is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms:
  • u00a0u00a0
  • *Efficacy for these organisms were studied in fewer than 10 infectionsu00a0
  • ZYMAXIDn is au00a0quinolone antimicrobial indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms:
  • 1
  • Day 1: Instill one drop every two hours in the affected eye(s) while awake, up to 8 times on Day 1.
  • u00a0u00a0
  • Days 2 through 7: Instill one drop two to four times daily in the affected eye(s) while awake on Days 2 through 7. ()
  • u00a0
  • Ophthalmic solution: 0.5% gatifloxacin (5 mg/mL)
  • Ophthalmic solution: 0.5% gatifloxacin (5mg/mL) ()
  • ZYMAXIDu00a0is contraindicated in patients with a history of hypersensitivity to gatifloxacin, to other quinolones, or to any of the components in this medicationu00a0n n .
  • ZYMAXID is contraindicated inu00a0patients with a history of hypersensitivity to gatifloxacin, to other quinolones, or to any of the components in this medication. ()
  • No data
  • Hypersensitivity ()n
  • Growth of Resistant Organisms with Prolonged Use ()n
  • Corneal Endothelial Cell Injury ()
  • The following serious adverse reactions are described elsewhere in the labeling:
  • Most common adverse reactions occurring in u2265 1 % of patients included worsening of conjunctivitis, eye irritation, dysgeusia, and eye pain. ()
  • No data
  • ZYMAXID is a quinolone antimicrobial topical ophthalmic solutionu00a0for the treatment of bacterial conjunctivitis. u00a0Its chemical name is (u00b1)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid, sesquihydrate. Its molecular formula is CHFNO u00b7 1u00bdu00a0HO and its molecular weight is 402.42. Its chemical structure is:
  • u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0
  • u00a0u00a0u00a0u00a0nttu00a0u00a0u00a0u00a0u00a0ntnttu00a0u00a0u00a0u00a0u00a0ntnttu00a0u00a0u00a0u00a0u00a0ntnttu00a0u00a0u00a0u00a0u00a0ntu00a0u00a0u00a0u00a0u00a0u00a0u00a0u00a0
  • ZYMAXID is a clear, pale yellow, sterile, preserved aqueous solution with an osmolality of 260-330 mOsm/kg and a pH of 5.1-5.7.
  • ZYMAXIDn contains the active ingredient gatifloxacin 0.5% (5 mg/mL) and the inactive ingredients benzalkonium chloride 0.005%, edetate disodium,u00a0sodium chloride and purified water. ZYMAXID may contain hydrochloric acid and/or sodium hydroxide to adjust pH.
  • No data
  • Carcinogenesis
  • A statistically significant increase in the incidence of large granular lymphocyte (LGL) leukemia was seen in male rats treated with 100 mg/kg/day (approximately 405-fold higher than the MRHOD, on a mg/m basis). Fischer 344 rats have a high spontaneous background rate of LGL leukemia and the incidence in high-dose males only slightly exceeded the historical control range established for this strain. There was no increase in neoplasms among Fischer 344 rats given gatifloxacin in the diet for 2 years at doses averaging 47 mg/kg/day in males and 139 mg/kg/day in females (approximately 190- and 560-fold higher than the MRHOD, respectively), on a mg/m basis.
  • Mutagenesis
  • in vitro
  • in vitro
  • in vivo
  • Impairment of Fertility
  • In two randomized, double-masked, multicenter clinical trials, where patients 1-89 years of age were dosed for 5 days, ZYMAXIDn was clinically superior to its vehicle on day 6 in patients with conjunctivitis and positive conjunctival cultures. u00a0Clinical outcomes for the trials demonstrated clinical success (resolution of conjunctival hyperemia and conjunctival discharge) in 58% (193/333) of patients for the gatifloxacin-treated groups versus 45% (148/325) for the vehicle-treated groups. u00a0Microbiological outcomes for the same clinical trials demonstrated a statistically superior eradication rate for causative pathogens of 90% (301/333) for gatifloxacin vs. 70% (228/325) for vehicle. u00a0Please note that microbiological eradication does not always correlate with clinical outcome in anti-infective trials.
  • ZYMAXIDn (gatifloxacinu00a0ophthalmic solution) 0.5%u00a0is supplied sterile in a white, low density polyethylene (LDPE) bottle with a controlled dropper tip, and a tan, high impact polystyrene (HIPS) cap in the following size:
  • 2.5 mL in 5 mL bottle: NDC 0023-3615-25
  • Storage:n- u00a0
  • Avoiding Contamination of the Product
  • Potential for Hypersensitivity Reactionsn- [see Warnings and Precautions n- (n- Arrayn- ) and Contraindication (n- Arrayn- )n- ]n- .
  • u00a9 2017u00a0Allergan. All rights reserved.
  • All trademarks are the property of their respective owners.nttu00a0u00a0u00a0u00a0u00a0nt
  • Patented. See www.allergan.com/patentsIrvine, CA 92612Made in the U.S.A.
  • 72366US14
  • PRINCIPAL DISPLAY PANELNDC 0023-3615-25n n n n u00a0Rx Only Sterile

Browse Our Services And Processes

Comparator Sourcing for Clinical Trials

Comparator Sourcing for Clinical Trials

GNH India brings over 10 years of experience in Comparator

Read More

Name Patient Supply

Name Patient Supply

Today, the exact cause for many rare diseases remains unknown

Read More

Validated Cold Chain Shipment

Validated Cold Chain Shipment

With shifting of pharma industry from synthetic molecules to biologic

Read More

Clinical Trials Supply

Clinical Trials Supply

STOP SOURCING..... START SMART SOURCING...... COME STRAIGHT TO THE SOURCE

Read More

Pharmaceutical Contract Manufacturing

Pharmaceutical Contract Manufacturing

GNH Provides Contract Manufacturing services for: Generic Medicines with following

Read More

Pricing

Pricing

PRICING POLICY Terms of sales are typically prepaid, unless otherwise

Read More

Disclaimer

Please see the Legal Notice for detailed terms and disclaimers. The Legal Notice governs the use of this Website and by accessing and using this Website you agree to be bound by and accept the Legal Notice.

Browse from other international pharmaceuticals

General

64020 Products

GNH India Brings to over 64036 Product SKUs from India all at 1 place with easy access and global deliveries.

US NDC

71245 Products

GNH India Brings to over 71252 Product SKUs from India all at 1 place with easy access and global deliveries.

Canadian DIN

51046 Products

GNH India Brings to over 51047 Product SKUs from India all at 1 place with easy access and global deliveries.

Swiss Drugs

150 Products

GNH India Brings to over 150 Product SKUs from India all at 1 place with easy access and global deliveries.

NZ Drugs

13296 Products

GNH Brings to over 13298 Product SKUs from India all at 1 place with easy access and global deliveries.

FAQ

Check out our delivery process

Can’t find what
you’re looking for?

Contact US
Pharmexcil
DB
FIEO-2016
SiteLock

Copyright © 2024 GNHIndia .com. All Rights Reserved. Please read Legal Notice for further details.

Disclaimer: Product names, logos, brands and other trademarks featured or referred to are the property of their respective trademark holders.